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excluded if their target population did not specifically focus on women 
recruitment. We estimated the frequency of RI with which women were 
recruited by pooling across studies that presented data for RI used to enhance 
participation in HRS as proportions and 95% confidence intervals (CIs) for each RI 
using random-effects model. STATA (version 11.0) was used to perform the 
analysis. RESULTS: We analyzed 15 interventional studies (n=9266) and 5 
observational studies (n=2536). RI were classified into four categories; Referral, 
Social marketing (SM), health system (HS) and community outreach (CO). SM 
used in 96%, referrals 77%, CO in 50% and HS 88% studies. In aggregate, SM lead 
to 63.9%(63-64.7), referrals 14.5% (13-15.2), CO 20%(19-22), and HS 13.6% (13-14.7) 
participant recruitment. SM was the most effective RI in 69% (14 of 20) of studies 
it was attempted. CONCLUSIONS: This study found that social marketing as 
most effective strategy in the studies it attempted compared to other 
intervention.The identification of such RI to enhance participation in HRS should 
help researchers to develop strategies that will keep to a maximum participation 
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OBJECTIVES: In 2012 CONITEC (Brazilian National Commission of HTA) rules, 
information checklist and timelines, were officially established for medicines, 
procedures and devices. One year after the start of this new process, 132 
processes were submitted to the commission. The objective of this research is to 
present a quantitative and qualitative analysis of this process. METHODS: 
Analysis of the CONITEC different reports until Dec 31 2012 in relation to the 
established public health care programs and the 2012-2015 Brazilian national 
health plan. RESULTS: Of the 132 submitted processes, 98 were analyzed until 
Dec 31 2012. 40 submissions were recused by non-conformity with the 
documentation checklist; 35 had a positive answer for inclusion in the public 
health care reimbursement system and of them 24 were submitted by the 
government itself, 10 by both the government and manufacturers and 1 by the 
manufacturer alone; 23 did not achieve a positive recommendation; 34 
submissions are still under evaluation. Technologies that were incorporated 
have a public health care program. Inclusion occurred because the technology 
was considered to have enough clinical evidence, represent savings for the 
system or was considered effective and although not representing savings to the 
system the government considered it an investment in a strategic disease. The 
main reasons for not achieving a positive recommendation for inclusion were: 
insufficient clinical data, inadequate economic studies to the local scenario, 
negative evaluations from other commissions (NICE and Scottish medicines 
consortium, mainly) and inexistence of real world public data. CONCLUSIONS: 
Considering these results, a well-established clinical data program, stakeholders 
mapping, understanding of the local needs and scenario, careful analysis of the 
implications for the system of the technology inclusion and a very well planed 
market access strategy are mandatory before submitting new health technology 
to the evaluation commission, which is the end process of a negotiation.  
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OBJECTIVES: In order to improve the medication access for the Brazilian citizens, 
the CAP (Price Coefficient), which is the mandatory minimum discount, was 
regularized by the Brazilian Chamber of Pharmaceutical Market Regulation in 
December 2006. This discount must be used not only on the prices of high cost 
drugs, when they are purchased by the government, but also on every 
medication which are obtained by judicial process. The objective of this study is 
to present a case study which evaluates the fulfillment of CAP on the acquisition 
by judicial process of a medication indicated to treat a rare disease. METHODS: 
Economic information (number of units sold and total sales from governmental 
acquirements per month, number of patients treated by the new drug) between 
December 2010 and November 2012 were provided by the pharmaceutical 
industry from two different via. One of them is the mandatory annual report of 
commercialization, which is an instrument to monitor the Brazilian 
pharmaceutical market. The other information source is the requirement, which 
was made when the entry price was established for that specific technology. 
RESULTS: During the period of the study, all the medications were bought 
through the judicial process by the SUS (Brazilian Public Health System) and the 
CAP was properly used; the sale price practiced was much close to the maximum 
government sale price. However, there are differences between the information: 
the number of patients, the number of units sold and the total sales. 
CONCLUSIONS: Especially in cases of medications with high treatment cost, it is 
very important to assess the use of the CAP discount by different way of 
requirement, not only by the annual commercialization report. The CAP discount 
allowed improving the medication access by SUS with lowest price, more than 
20% of the discount on the maximum fabric price.  
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OBJECTIVES: Resolution nº 2/2004 dictates the criteria to establish the entry 
prices of new medicines in Brazil. According to it, products are divided into: new 
products and new presentations. This research will focus in new products, which 
are classified in: Category I - new product (patented molecule) with scientific 
evidences of benefit when compared to others of same therapeutic indication 
(greater efficacy; same efficacy with decreased side effects or same efficacy with 
lower global cost). Category II - new products not classified as I. Price analysis 
follows a model of price cap, including two constraints: lowest international 
price (based on a list of nine countries plus where the product is produced) and 
cost of treatment, based on an elected comparator. Price for Category I is based 
on the lowest international price only and, for Category II, the cost of treatment 
with the chosen comparator and international prices, the lowest of them. The 
goal of this research is to evaluate the application of price regulation since 
Resolution nº 2/2004 publication and its consequences regarding to decreasing 
the costs of medicines for the society. METHODS: Data of price analysis (new 
products) performed by Office of Economic Assessment of New Technologies of 
Brazilian Health Surveillance Agency (Anvisa), which supports CMED decisions, 
were evaluated (2004–2011). RESULTS: In * years, 209 new molecules (563 
presentations) were analyzed. The mean difference found between the price 
pleaded by laboratories and the price determined after analysis was: Category I 
21%; Category II 39%. Only 7% of new products proved to be innovative, while 
93% of the new products were classified as II (either not under patent or without 
proven benefit). CONCLUSIONS: Resolution n° 2/2004 has led to lower entry 
prices and, consequently, decreased the cost to the private and public sector, 
improving the efficiency of health care.  
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OBJECTIVES: Previous research demonstrated that prices do not vary across 
countries based on macroeconomic variables. We present a framework 
comparing profits under differential pricing with homogenous pricing. 
METHODS: We developed a model based on monopolistic pricing theory to solve 
for a static efficiency solution. The demand curve for a given market, i, is Q=ai-
biP, where Q is quantity and P is price. For a given market, factors that could 
influence the shape of our demand curve (parameters ai and bi) include 
purchasing power, burden of disease, drug access in other markets, 
completeness of the health system, income and wealth equality, ease of market 
access, and market stability. Given these factors, we show a theoretic solution 
for 2 markets (one “rich” and one “poor”) and compare the profits under our 
model versus a single global price system. We assume the “rich” market (lower 
price elasticity) and “poor” (higher price elasticity) market have demand curves 
Q=2-0.1P and Q=2-0.5P, respectively. RESULTS: For i=1,2, the profit, π, from a 
single price is π=PQ-cQ=P(a1-b1P+a2-b2P)-c(a1-b1P+a2-b2P). The optimal price is then 
P=(a1+a2+c(b1+b2))/(2(b1+b2)). If the monopolistic firm does indeed price 
discriminate, the optimal price for market i would be Pi=(ai+cbi)/(2bi). Our findings 
indicate that the potential profit between a single price scenario and a price 
discriminating scenario increases as the elasticities bi vary. In our two market 
example, the single price (SP) model has a profit πSP=4.82 compared with a price 
discriminant (PD) model of profit πPD=10.15. Not only is πPD over twice the size of 
πSP, but in some cases the total output also increases, which results in welfare 
gain. CONCLUSIONS: The optimal pricing solution for pricing pharmaceuticals 
around the world implies prices should vary based on economic factors. This is 
not currently observed in practice, which results in lost rents.  
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OBJECTIVES: Economic analysis has traditionally been utilized in health care 
decision making when applied to high-cost medical technologies. However, 
health care decision making in the United States (US) seldom considers ethical 
principles such as distributive justice. There tends to be an inherent conflict 
between cost-effectiveness and patient’s interest. How these conflicts are 
resolved, needs to be informed by both economic and ethical analysis. The study 
objective is to assess the extent to which ethical principles are utilized along 
with economic analysis in health care decision-making. METHODS: A systematic 
literature search was conducted among peer-reviewed journals in electronic 
databases such as Scopus and EconLit. No time-frame was stipulated for these 
searches and inclusion was not limited to the language or the country where the 
study was conducted. RESULTS: A total of 81 articles were identified and 17 
studies were reviewed based on the inclusion/exclusion criteria. The review 
supported an integration of evidence, economics and ethics in health technology 
assessment (HTA). Some ethical perspectives discussed in the HTA included: 
decisions should be accountable to democratic procedure and citizen 
participation; balance between utility and fairness; and inherent conflict 
between provider fiduciary responsibility to patients and cost effectiveness. 
Developing criteria for allocation of high-cost medical technology was the most 
discussed issue. A survey of health professionals from Western Europe 
documented that 90% believed ethical analysis was important in HTA but was 
constrained by practical issues. CONCLUSIONS: The incorporation of ethical 
perspectives into health care decision-making is still in its infancy. No efforts 
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have been taken so far to assess the importance associated by the health care 
decision-makers to incorporate ethical principles into practice. The review 
serves as an initial basis for a survey to study US decision-makers’ perspectives 
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OBJECTIVES: To give an overview of recent PDPs between the pharmaceutical 
industry, the public sector, International Health Organizations (IHOs) and 
academia and draw best practices from two case studies, the Medicines for 
Malaria Venture (adaptive PDP) and the Malaria Vaccine Initiative (innovative 
PDP). METHODS: We surveyed the ‘Health Partnerships Database’ (HPD) to list 
PDPs to date. We searched for partnerships involving product development of 
drugs, vaccines and other pharmaceutical and diagnostics products. For the case 
studies, we analysed websites of the specific PDPs. RESULTS: The HPD lists 19 
PDPs, which can be classified into two categories: adaptive PDPs, i.e. research 
and development (R&D) initiatives focused on tailoring existing products to 
developing countries’ needs, and innovative PDPs, i.e. R&D initiatives focused on 
developing new products to address developing countries’ diseases. Existing 
PDPs focus on R&D of drugs (8 PDPs), vaccines (7 PDPs) and preventive and 
diagnostic techniques (4 PDPs) for diseases such as tuberculosis (TB, 5 PDPs), 
malaria (6 PDPs), meningitis (1 PDP) and HIV/AIDS (6 PDPs). Meanwhile, recently 
developed PDPs are tailored as an access-to-market strategy for essential and 
neglected disease treatments in developing countries (4 PDPs). In-depth analysis 
of two PDPs showed that 1) assessment of specific health care needs in 
developing countries prior to partnership initiation; 2) local government 
engagement in partnerships; 3) sustainability of funding flow accompanied by 
national expertise building; and 4) monitoring, reporting and transparent sharing 
of results are crucial for the success of PDPs. CONCLUSIONS: Multinational 
pharmaceutical companies are increasingly dedicating part of their development 
pipeline to developing-country diseases and turning to IHOs as strategic partners 
to secure market knowledge and access in these countries. However, most 
collaborations still happen around the “big three” diseases, Malaria, HIV/AIDS 
and TB.  
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VALUE-BASED DRUG INSURANCE DESIGN FOR INSUREDS WITH FIVE HIGH-
COST CONDITIONS  
Olchanski N1, Milstein AS2, Chambers JD1, Neumann PJ1 
1Tufts Medical Center, Boston, MA, USA, 2Stanford University School of Medicine, Stanford, CA, 
USA  
OBJECTIVES: The goal of value-based insurance design (VBID) is to set encourage 
use of high-value therapies and discourage use of low-value ones by appealing to 
evidence of value, rather than a drug’s price, when tiering drugs and setting 
copayment levels. The aim of this study was to simulate the impact of an 
illustrative VBID approach on savings and health gains. METHODS: We used 
simulation to model an impact of a value-based formulary where drugs with less 
favorable cost-effectiveness (CE) had higher co-pays, and those with more 
favorable clinical effectiveness and CE were tiered with lower co-pays. Model 
inputs included drug utilization and cost data from the Medical Expenditure 
Panel Survey (MEPS) for 2008 and CE and health gain data from the published 
literature (Tufts CEA Registry). Estimates of behavioral effects of changing co-pay 
amounts on drug utilization were based on published literature. Modeled 
conditions included lipid disorders, hypertension, diabetes, esophageal 
disorders, and depression. In sensitivity analyses we ran the model using a large 
health plan’s 2010 drug cost and utilization data. RESULTS: In the esophageal 
and lipid-lowering scenarios, the total annual prescription costs decreased (3-
9%), in the hypertension scenario costs remained roughly the same, and in 
depression and diabetes costs increased slightly (2-4%). Total costs of care 
decreased in all but one scenario by 1-2%, and remained steady in the 
hypertension scenario. Health benefits also showed a positive impact across all 
scenarios, increasing total quality-adjusted life years gained by 118,000 to 
254,000, about 1%. The results were similar in scenarios using health plan data. 
CONCLUSIONS: The simulation illustrates the importance of evolving from the 
prevalent sub-optimal practice of tiering therapies based largely on drug costs to 
tiering based on overall value.  
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health 
care budget constraints will pressure managed care plans to consider restricting 
market access. Coverage and reimbursement of ten FDA-designated orphan 
drugs (alpha-glucosidase, bexarotene, bosentan, galsulfase, idursulfase, iloprost, 
laronidase, mecasermin, nitisinone, plerixafor) were analyzed for seven popular 
Medicare PDP (BCBS Rx, AARP Medicare Rx Preferred, Cigna Medicare Rx Plan 
One, Humana Enhanced, Aetna/CVS, EmblemHealth, UnitedHealthcare). 
METHODS: Formulary tier structure, monthly retail costs and utilization 
restrictions (UR)—pre-authorization (PA), quantity limits (QL) and step therapy 
(ST)—were obtained from CMS (www.medicare.gov). UR were assigned point 
values reflecting most to least restrictive—QL, 1; ST, 2; PA, 3; exclusion from 
formulary, 6. Each drug-plan combination can be assigned a maximum of 6 
points. Disease prevalences were obtained from a variety of sources. RESULTS: 
Monthly retail prices ranged from $782.45 (laronidase) to $11,845.25 
(mecasermin). Iloprost was most frequently excluded from formularies (2) and 
was subject to PA from the remaining five plans. The most frequently PA drug 
was mecasermin (6). There was slight negative correlation between price and 
prevalence of the disease for which the drugs were indicated (r2=0.080). There 
was a slight positive correlation between price and the number of UR points (r2= 
0.046). There was virtually no correlation between UR points and disease 
prevalence (r2=0.004). However, there is a moderate correlation between the 
number of plans that implement PA for a drug and that drug’s price (r2=0.322). 
CONCLUSIONS: With a wide range of drug prices, there is virtually no correlation 
between the number of UR points, drug price and disease prevalence. However, it 
is clear that PA is perceived to be the most effective cost-saving measure as it is 
used most for the more expensive drugs.  
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OBJECTIVES: The purpose of the study was to assess the relationship of 
pharmaceutical expenditures (PE) and other social and economic factors on life 
expectancy for different age groups in Organisation for Economic Co-operation 
and Development (OECD) countries. METHODS: This retrospective study 
analyzed data from the OECD database on the association between life 
expectancy in 2010 and PE, social/lifestyle (tobacco, alcohol, fruits, vegetables, 
and sugar consumption), and economic (health care expenditures and gross 
domestic product (GDP)) factors from a sample of 27 developed countries. Data 
were pooled according to gender at 40, 60, and 65 years while controlling for the 
lag variables of alcohol and tobacco (lagged 20 years), food intake variables (7 
years), and economic factors (12 years). All variables were transformed via 
logathrimic form to yield full elasticities. A bootstrapped random intercept 
regression model with sandwich estimators was conducted to determine which 
social and health factors were associated with a change in life expectancy. 
RESULTS: The mean life expectancy for males was 39.02±2.30 years for age 40, 
21.44±1.65 years for age 60, and 17.58±1.39 years for age 65. The mean life 
expectancy for females was 43.22±2.09 years for age 40, 25.21±1.68 years for age 
60, and 20.90±1.57 years for age 65. Results of the regression of life expectancy 
indicated significant associations (p≤0.05) of: male gender (coefficient=−0.146. CI: 
−0.157-0.135); age group of 60 years (−0.570, CI: −0.583-0.558); age group of 65 
years (−0.763, CI: −0.777-0.750); calorie intake (−0.144, CI: −0.246-0.041); fruit and 
vegetable intake (0.06, CI:0.036-0.084); overall health care expenditures (−0.047, 
CI: −0.092-0.001); and GDP (0.252, CI:0.189-0.314). Pharmaceutical expenditures 
were not associated with change in life expectancy for any age group. 
CONCLUSIONS: Across 27 OCED countries, specific food intake, GDP, and health 
care expenditures were significantly associated with altering life expectancy. 
Increased PE was not significantly associated with life expectancy.  
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OBJECTIVES: This study compares homeless patients’ utilization of the urban 
emergency department (ED) in the United States (US) with non-homeless 
patients and examines the relationship between homelessness and frequency of 
ED use, arrival to the ED by ambulance, waiting time to be seen, length and type 
of ED visit. METHODS: The emergency department component of the 2009 
National Hospital Ambulatory Care Survey database (NHAMCS-ED) was used for 
this cross-sectional, descriptive analysis. Patients were included if their patient 
residence was homeless or private residence and if they visited an urban ED. 
Descriptive statistics, bivariate analyses, and logistic regression were used to 
examine the relationship between demographics and ED use variables with 
homelessness. Nationally representative weights were applied to the estimates. 
RESULTS: The weighted sample size was 100,847,969 patient visits. A total of 
n=636,399 (0.63%) of the patients were homeless. The mean age of homeless 
patients was 44.0 years (95% CI: 41.7-46.3) compared to 34.7 years for non-
homeless patients (95% CI: 33.5-35.9, p<0.0001). The majority of homeless 
patients were male (75.9%) versus only 44.9% of non-homeless patients 
(p<0.0001). More homeless patients arrived to the ED via ambulance (45.2 vs. 
14.9%, p<0.0001). Homeless patients had a significantly different length of ED 
visit and number of ED visits in the past 12 months (both p=0.007) than non-
homeless patients. Homeless patients were more likely to be older (OR=1.02, 95% 
CI: 1.003-1.040), male gender (OR=3.34, 95% CI: 1.191-9.349), arrive to the ED via 
ambulance (OR=7.56, 95% CI: 4.045-14.137), have a longer length of ED visit 
(OR=1.002, 95%CI: 1.001-1.003), and have a past visit to the ED in the last 12 
months (OR=1.06, 95%CI: 1.033-1.080) than non-homeless patients. 
CONCLUSIONS: In 2009, homeless patients who visited US urban emergency 
departments were significantly different than non-homeless patients in their 
demographics, frequency, access, and pattern of ED use.  
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